Jump to content

Search the Community

Showing results for tags 'Dose'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 1 result

  1. More from this year's Annual General Meeting of the American Society of Clinical Oncologists (ASCO). Zometa (zoledronic acid), when given to men with bone metastases, has been shown to both delay damage to bones and to extend life. The current standard of care is to give to Zometa every 4 weeks. Research presented at the ASCO Annual Meeting gave the results of a trial which compared giving Zometa every 12 weeks with giving it every 4 weeks. The trial studied 1,822 patients (with three different diseases - Prostate Cancer, breast cancer and multiple myeloma) for a period of 2 years. The trial found that administering Zometa every 12 weeks was not inferior to administering it every 4 weeks. There were no significant differences in side effects between the 2 different dosing schedules. Zometa is given to the patient via an intravenous infusion. There are obvious benefits for the patient in only having to have the treatment every 12 weeks, instead of every 4 weeks. There is also the benefit that a 12 weekly dosing schedule is cheaper than a 4 weekly dosing schedule. It is likely that this research will lead to a change in the frequency of treatments for patients on Zometa. Reference: A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. http://meetinglibrary.asco.org/content/147845-156
×
×
  • Create New...